Press Room

News / Dec 05, 2021

Hovione Cork renews its certification of The Business Working Responsibly Mark

A recognition for CSR practices at the site and its positive impact on both the workplace and the wider community

Hovione wins business working responsibility mark

Recently the Hovione Cork site achieved certification of The Business Working Responsibly Mark for the second time, having first achieved the Mark in 2018. The Mark is the leading independently audited standard for Corporate Social Responsibility (CSR) and Sustainability certification in Ireland and is based on ISO26000. The Mark assessment process involved a root to branch review of Hovione's corporate social responsibility and sustainability management systems across five pillars - Governance, Workplace, Marketplace, Environment and Community.

 

“The awarding of the certification for another 3 years is great recognition of the work and dedication that the team in Cork have to continuously improving and developing the CSR standards and practices at the site and its positive impact on both the workplace and the wider community”, said Louise Dennehy.

Business Working Responsibility Mark logo | Hovione

























 

The process for recertification began in April this year lead by Louise Dennehy, HR Business Partner, Marguerite Lynch, HSE Manager - Environment, Bruno Dias, OpEx Specialist and Maureen O'Leary, Procurement Manager with the audit taking place virtually at the end of October. Along with a full process and documentation review, 4 team members were interviewed by the assessor on their knowledge, awareness and understanding of the company’s CSR activities.

 

You might be also interested in:









 

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026